Biomarkers of collagen type i metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure

Journal of Cardiovascular Medicine

Volumn 15, Issue 6, 2014, Pages 463-469

  Löfsjögard, Johan ^a   Kahan, Thomas ^a   Díez, Javier ^b,c   López, Begoña ^b   González, Arantxa ^b   Edner, Magnus ^a   Henriksson, Peter ^a   Mejhert, Märit ^a,d   Persson, Hans ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d ERSTA HOSPITAL   (Sweden)

Author keywords

Collagen; Echocardiography; Heart failure; Myocardial fibrosis; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARBOXYTERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE I; COLLAGEN TYPE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIASTOLE; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE SIZE; HUMAN; IMMUNOASSAY ANALYZER; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTPATIENT CARE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SYSTOLIC HEART FAILURE; BLOOD; ECHOGRAPHY; FIBROSIS; HEART FAILURE; HEART MUSCLE; HEART STROKE VOLUME; HEART VENTRICLE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COLLAGEN TYPE I; DIASTOLE; FEMALE; FIBROSIS; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PEPTIDES; RETROSPECTIVE STUDIES; STROKE VOLUME;

EID: 84907235563     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/01.JCM.0000435617.86180.0b     Document Type: Article

References (31)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787-1847.
2. Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? Cardiol Clin 2007; 25:487-495.
3. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994; 89:151-163.
4. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16:1031-1041.
5. Assayag P, Carre F, Chevalier B, et al. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res 1997; 34:439-444.
6. Weber KT, Sun Y, Tyagi SC, Cleutjens JP. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994; 26:279-292.
7. Sun Y, Weber KT. Infarct scar: A dynamic tissue. Cardiovasc Res 2000; 46:250-256.
8. Weber KT. Fibrosis and hypertensive heart disease. Curr Opinion Cardiol 2000; 15:264-272.
9. D'Ascia C, Cittadini A, Monti MG, et al. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium. Eur Heart J 2006; 27:201-206.
10. Ló pez B, Gonzá lez A, Díez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2014; 121:1645-1654.
11. Díez J, Querejeta R, Ló pez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105:2512-2517.
12. Querejeta R, Varo N, Ló pez B, et al. Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101:1729-1735.
13. Mejhert M, Kahan T, Persson H, Edner M. Limited long term effects of a management programme for heart failure. Heart 2004; 90:1010-1015.
14. Mejhert M, Kahan T, Edner M, Persson HE. Sex differences in systolic heart failure in the elderly: The prognostic importance of left ventricular mass in women. J Womens Health 2008; 17:373-381.
15. MejhertM, Linder-Klingsell E, Edner M, et al. Ventilatory variables are strong prognostic markers in elderly patients with heart failure. Heart 2002; 88:239-243.
16. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30:1527-1533.
17. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296:2209-2216.
18. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194-202.
19. Janicki JS, Brower GL. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Card Fail 2002; 8:S319-S325.
20. Ló pez B, Gonzá lez A, Querejeta R, et al. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006; 48:89-96.
21. Siwik DA, Colucci WS. Regulation of matrix metalloproteinases by cytokines and reactive oxygen/nitrogen species in the myocardium. Heart Fail Rev 2004; 9:43-51.
22. Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (Ephesus) study. Circulation 2009; 119:2471-2479.
23. Manhenke C, Orn S, Squire I, et al. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol 2014; 150:277-282.
24. Burnett JC Jr. Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon. J Cardiol 2006; 48:235-241.
25. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25:227-234.
26. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin IIinduced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995; 96:1059-1065.
27. Ogawa Y, Tamura N, Chusho H, Nakao K. Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart. Can J Physiol Pharmacol 2001; 79:723-729.
28. Díez J, Laviades C, Mayor G, et al. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995; 91:1450-1456.
29. Mü ller-Brunotte R, Kahan T, Ló pez B, et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertension 2007; 25:1958-1966.
30. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000; 102:2700-2706.
31. Garcia-Bolao I, Lopez B, Macias A, et al. Impact of collagen type I turnover on the long-term response to cardiac resynchronization therapy. Eur Heart J 2008; 29:898-906.